Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability resulting in increased usage worldwide. Likewise, insulin pumps are becoming smarter and easier to use. More recently, sensor insulin pump therapy has been improved, with great benefits for patients in optimizing blood glucose control and preventing hypoglycemia. Further progress has been made with the introduction of advanced closed-loop control (CLC) systems that combine both technologies with the addition of an algorithm that allows hypo and hyperglycemia to be minimized through self-correcting boluses.
Various clinical trials conducted to test these new technologies have reported improvements in HbA1c, CGM-based glycemic parameters, and patient satisfaction. At the same time, new devices, including interoperable systems, are constantly being introduced onto the market, generating expectations in many patients. Few studies report long-term clinical data in daily life, information on how to initiate patients to use these technologies, on how to address the barriers in the daily use of these technologies, on reimbursement by public health systems.
This Research Topic welcomes manuscripts in the form of reviews, research papers, case series, or even case reports. Articles should focus on real-world data, clinical practice, diabetes technology in children, adolescents, and young adults, and provide practical approaches on their use. Papers on blood glucose control, quality of life, or any topic related to both will be considered for publication.
Special attention will be given to these topics:
• insulin pumps
• continuous glucose monitoring
• sensor augmented pumps
• closed loop control systems
• automated decision support systems
• telemedicine
• technology education
• technology reimbursement
We welcome the authors to propose any other topic not included in the list if deemed relevant, sending by e-mail the proposal to the editorial staff if it is not present in the list. We will evaluate if it falls within the scope of the problem.
Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability resulting in increased usage worldwide. Likewise, insulin pumps are becoming smarter and easier to use. More recently, sensor insulin pump therapy has been improved, with great benefits for patients in optimizing blood glucose control and preventing hypoglycemia. Further progress has been made with the introduction of advanced closed-loop control (CLC) systems that combine both technologies with the addition of an algorithm that allows hypo and hyperglycemia to be minimized through self-correcting boluses.
Various clinical trials conducted to test these new technologies have reported improvements in HbA1c, CGM-based glycemic parameters, and patient satisfaction. At the same time, new devices, including interoperable systems, are constantly being introduced onto the market, generating expectations in many patients. Few studies report long-term clinical data in daily life, information on how to initiate patients to use these technologies, on how to address the barriers in the daily use of these technologies, on reimbursement by public health systems.
This Research Topic welcomes manuscripts in the form of reviews, research papers, case series, or even case reports. Articles should focus on real-world data, clinical practice, diabetes technology in children, adolescents, and young adults, and provide practical approaches on their use. Papers on blood glucose control, quality of life, or any topic related to both will be considered for publication.
Special attention will be given to these topics:
• insulin pumps
• continuous glucose monitoring
• sensor augmented pumps
• closed loop control systems
• automated decision support systems
• telemedicine
• technology education
• technology reimbursement
We welcome the authors to propose any other topic not included in the list if deemed relevant, sending by e-mail the proposal to the editorial staff if it is not present in the list. We will evaluate if it falls within the scope of the problem.
